NASDAQ:AMGN - Amgen Stock Price, Forecast & News

Amgen's stock was trading at $198.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AMGN stock has decreased by 0.2% and is now trading at $198.27. View which stocks have been mosted impacted by Coronavirus.

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 10 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amgen.

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Amgen.

Amgen, Inc. (NASDAQ:AMGN) posted its earnings results on Thursday, January, 30th. The medical research company reported $3.64 earnings per share for the quarter, beating the Zacks' consensus estimate of $3.47 by $0.17. The medical research company had revenue of $6.20 billion for the quarter, compared to analysts' expectations of $6.04 billion. Amgen had a net margin of 33.57% and a return on equity of 85.52%. The company's revenue for the quarter was down .5% compared to the same quarter last year. During the same period last year, the business posted $3.42 earnings per share. View Amgen's earnings history.

Amgen declared a quarterly dividend on Wednesday, March 4th. Stockholders of record on Monday, May 18th will be paid a dividend of $1.60 per share on Monday, June 8th. This represents a $6.40 annualized dividend and a yield of 3.23%. The ex-dividend date is Friday, May 15th. View Amgen's dividend history.

Amgen updated its FY20 earnings guidance on Thursday, January, 30th. The company provided EPS guidance of $14.85-$15.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.10. The company issued revenue guidance of $25.0-$25.6 billion, compared to the consensus revenue estimate of $25.41 billion.

25 equities research analysts have issued 12 month price targets for Amgen's stock. Their forecasts range from $185.00 to $277.00. On average, they expect Amgen's stock price to reach $238.90 in the next year. This suggests a possible upside of 20.5% from the stock's current price. View analysts' price targets for Amgen.

Media coverage about AMGN stock has trended positive recently, InfoTrie reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amgen earned a daily sentiment score of 2.4 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutAmgen.

Some companies that are related to Amgen include Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), Alibaba Group (BABA), NVIDIA (NVDA), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), Home Depot (HD) and JPMorgan Chase & Co. (JPM).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by a number of retail and institutional investors. Top institutional investors include Capital Research Global Investors (5.99%), Wealth Quarterback LLC (5.28%), State Street Corp (4.41%), FMR LLC (4.12%), Geode Capital Management LLC (1.70%) and Bank of New York Mellon Corp (1.15%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar, Sean E Harper and Tyler Jacks. View institutional ownership trends for Amgen.

AMGN stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Ruffer LLP, Renaissance Technologies LLC, PGGM Investments, Man Group plc, DekaBank Deutsche Girozentrale, Franklin Resources Inc., and Franklin Resources Inc.. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, and Ronald D Sugar. View insider buying and selling activity for Amgen.

AMGN stock was purchased by a variety of institutional investors in the last quarter, including Wealth Quarterback LLC, Norges Bank, Capital Research Global Investors, Johanson Financial Advisors Inc., CI Investments Inc., Annex Advisory Services LLC, Los Angeles Capital Management & Equity Research Inc., and MUFG Securities EMEA plc. View insider buying and selling activity for Amgen.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMGN stock can currently be purchased for approximately $198.27.

Amgen has a market capitalization of $116.94 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe. View additional information about Amgen.

The official website for Amgen is http://www.amgen.com/.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]